REGENERON PHARMACEUTICALS, INC.·4

Aug 6, 4:03 PM ET

STAHL NEIL 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Aug 6, 2024

Insider Transaction Report

Form 4
Period: 2024-08-02
STAHL NEIL
SVP Res and Dev Sciences
Transactions
  • Exercise/Conversion

    Common Stock

    2024-08-02$555.67/sh+23,638$13,134,92774,637 total
  • Tax Payment

    Common Stock

    2024-08-02$1093.49/sh18,441$20,165,04956,196 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2024-08-0223,63845,000 total
    Exercise: $555.67Exp: 2025-12-16Common Stock (23,638 underlying)
Holdings
  • Common Stock

    (indirect: By 401(k))
    5,849
  • Common Stock

    (indirect: By Trust)
    4,605
Footnotes (1)
  • [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT